New Highs For KPJ Healthcare As Revenue Breaks Records
New Highs For KPJ Healthcare As Revenue Breaks Records
As per the analysts' analysis on the operational front, KPJ saw increased patient visits, with outpatient visits rising by 2% and inpatient visits increasing by 7% year-on-year, bringing the total patient visits to 887,665 in 3Q24. The company's bed occupancy rate also improved by 6 percentage points quarter-on-quarter to 72%, as the number of operational beds rose by 42% to 3,787.KPJ Healthcare Bhd (KPJ) has received positive updates from analysts, with both RHB Investment Bank Bhd (RHB Research) and MIDF Amanah Investment Bank Bhd (MIDF Research) maintaining BUY calls on the company. RHB Research has raised its target price to RM3, offering a 29% upside, while MIDF Research maintained a target price of RM2.54, reflecting a 9% expected return.
KPJ醫療有限公司(KPJ) 收到分析師的積極反饋，RHb投資銀行有限公司(RHb Research)和MIDF阿馬納投資銀行有限公司(MIDF Research)均對該公司維持買入評級。RHb Research將目標價提高至RM3，提供29%的上漲空間，而MIDF Research維持目標價爲RM2.54，預計回報爲9%。
KPJ recently reported a strong performance in 3Q24, with a 29% year-on-year (YoY) increase in core earnings to RM86 million, which contributed to a total of RM211 million for the first nine months of 2024, accounting for 74% and 73% of RHB Research and street's full-year estimates, respectively.
KPJ最近報告了2024年第三季度的強勁業績，核心盈利同比增長29%，達到8600萬令吉，2024年前九個月的總營業收入爲21100萬令吉，分別佔RHb Research和市場全年預估的74%和73%。
The company's highest-ever revenue of RM1.003 billion in 3Q24, up 14% from the previous year, was driven by robust patient traffic and an improved patient case mix. As a result, the core profit surged by 29%, and an interim dividend of 1.15 sen per share was declared, up from 0.8 sen in 3Q23.
公司在2024年第三季度創下的營業收入達10.03億令吉，同比增長14%，這一增長主要得益於患者流量的增加和患者病例組合的改善。因此，核心利潤激增29%，並宣佈了每股1.15仙的中期股息，較2023年第三季度的0.8仙有所增加。
As per the analysts' analysis on the operational front, KPJ saw increased patient visits, with outpatient visits rising by 2% and inpatient visits increasing by 7% year-on-year, bringing the total patient visits to 887,665 in 3Q24. The company's bed occupancy rate also improved by 6 percentage points quarter-on-quarter to 72%, as the number of operational beds rose by 42% to 3,787.
根據分析師對運營方面的分析，KPJ的患者就診量增加，其中門診就診量同比增長2%，住院就診量同比增長7%，2024年第三季度總患者就診量達到887,665人次。公司的牀位使用率也較上一季度提高了6個百分點，達到72%，運營牀位數量增加了42%，達到3,787張。
MIDF Research's analysis highlighted that KPJ's 9MFY24 revenue increased by 14.5% YoY to RM2.9 billion, with normalised earnings growing by 34.8% to RM247.3 million. The increase in patient visits and higher bed capacity were key contributors to this positive performance. Despite a decline in revenue from other business segments, including the divestment of its Australian operations in early 2024, KPJ's fundamentals remain strong. The Malaysian government's allocation of RM45.3 billion to the Ministry of Health in Budget 2025 is also expected to support the growth of the healthcare sector.
MIDF Research的分析指出，KPJ的2024財政年度前九個月營業收入同比增長14.5%，達到29億令吉，正常化盈利增長34.8%，達到24730萬令吉。患者就診量的增加和更高的牀位容量是這一積極表現的關鍵因素。儘管其他業務板塊的收入有所下降，包括2024年初剝離其澳大利亞業務，KPJ的基本面依然強勁。馬來西亞政府在2025年預算中分配給衛生部的453億令吉也有望支持醫療行業的增長。
Analysts from both RHB Research and MIDF Research are optimistic about KPJ's outlook, noting the company's strategic expansion of its bed capacity and talent acquisition initiatives. While competition in the healthcare sector and cost pressures remain key risks, analysts believed KPJ is well-positioned to maintain its positive trajectory.
來自RHb Research和MIDF Research的分析師對KPJ的前景表示樂觀，指出公司在牀位容量擴展和人才招聘方面的戰略。儘管醫療行業的競爭和成本壓力仍是主要風險，但分析師認爲KPJ已做好準備，能夠維持其積極的發展軌跡。
譯文內容由第三人軟體翻譯。
